On Friday, Royalty Pharma hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 89 the day before.
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks matches up against all other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they begin their largest climbs.
Looking For The Best Stocks To Buy And Watch? Start Here
Royalty Pharma is building a with a 34.20 buy point. See if it can clear the breakout price in volume at least 40% above average.
Royalty Pharma reported -68% EPS growth in the latest quarterly report. Revenue gains came in at 0%.
The company earns the No. 20 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
